Core Viewpoint - New peer-reviewed data supports masitinib's potential as a treatment for sporadic Alzheimer's disease through cognitive enhancement and neuroprotection [1][5][6] Group 1: Clinical Evidence - A new study from independent researchers indicates that masitinib improves cognitive functions in a mouse model of sporadic Alzheimer's disease, showing enhancements in memory, learning, and anxiety-like behaviors [3][4] - The study demonstrated that masitinib reduced toxic brain proteins, alleviated synaptic dysfunction, and suppressed microglial activation, which is linked to inflammation in Alzheimer's disease [4][5] - Results from a phase 2B/3 study (AB09004) showed that masitinib treatment significantly reduced cognitive impairment in patients with mild Alzheimer's disease, with a notable improvement in the mild impairment subgroup [8][9] Group 2: Regulatory and Development Status - The FDA and key EU countries have authorized a phase 3 clinical study (AB21004) to evaluate masitinib as a disease-modifying therapy for Alzheimer's disease [10][11] - The phase 3 study aims to confirm previous findings from the phase 2B/3 study regarding masitinib's efficacy in slowing cognitive deterioration and improving daily living activities [12] Group 3: Intellectual Property - AB Science has filed a patent application for masitinib's use in treating Alzheimer's disease, which, if granted, will provide protection until 2041 [13]

June 18, 2025 02:42 PM GMT China Healthcare | Asia Pacific Weekly Rx Express 2025.06.13 China Healthcare Asia Pacific Industry View Attractive Morgan Stanley does and seeks to do business with companies covered in Morgan Stanley Research. As a result, investors should be aware that the firm may have a conflict of interest that could affect the objectivity of Morgan Stanley Research. Investors should consider Morgan Stanley Research as only a single factor in making their investment decision. For analyst cer ...

Pivotal phase III SUNMO study demonstrated an 11.5 month median progression-free survival - three times longer than R-GemOx1This well-tolerated investigational combination therapy avoids traditional chemotherapy and may be suitable for outpatient community careThese data demonstrate Roche's commitment to providing options for diverse patient and healthcare system needs in this difficult-to-treat lymphoma Basel, 20 June 2025 - Roche (SIX: RO, ROG; OTCQX: RHHBY) presented today results from the phase III SUNM ...

Core Viewpoint - Anixa Biosciences, Inc. is set to host an investor webcast on June 26, 2025, to discuss its business strategy, therapeutic portfolio, market opportunities, and upcoming milestones [1][2]. Company Overview - Anixa is a clinical-stage biotechnology company focused on cancer treatment and prevention [4]. - The company is developing an ovarian cancer immunotherapy program in collaboration with Moffitt Cancer Center, utilizing a novel CAR-T technology called chimeric endocrine receptor-T cell (CER-T) technology [4]. - Anixa's vaccine portfolio includes vaccines for breast and ovarian cancer developed with Cleveland Clinic, as well as additional vaccines targeting high incidence malignancies in lung, colon, and prostate cancers [4]. - The company partners with renowned research institutions to explore emerging technologies for development and commercialization [4]. Webcast Details - The webcast will feature an introductory presentation by Dr. Amit Kumar, Anixa's Chairman and CEO, followed by a Q&A session for investors [2]. - Interested participants must pre-register to listen to the webcast and ask questions during the live event [3].

撰文丨王聪 编辑丨王多鱼 排版丨水成文 2022 年初，宾夕法尼亚大学的研究人员在 Science 期刊发表了一篇重磅研究论文 【1】 ，开发了一种 在体内原位生成 CAR-T 细胞的新技术 （ in vivo CAR- T） ，通过 注射脂质纳米颗粒 （LNP） 递送 mRNA，在体内重编程 T 细胞，使其识别心脏纤维化细胞，从而治疗心脏纤维化疾病。该方法类似于 mRNA 疫 苗，仅需简单注射，就能在体内生成 CAR-T 细胞疗法，有望解决当前 CAR-T 细胞疗法工艺复杂、周期长、价格高昂等关键难题。 不久后，该团队创立了一家名为 Capstan Therapeutics 的公司， 致力于将 in vivo CAR-T 技术应用于癌症、自身免疫疾病及纤维化疾病的治疗，该公司目前以 获得来自多家制药巨头及风投机构的 3.4 亿美元融资。该公司的 创始团队包括 Carl June （CAR-T 细胞治疗先驱） ， Drew Weissman （诺奖得主、mRNA 技 术奠基人） ， Jonathan Epstein （ in vivo CAR-T 技术发明人） 。 2025 年 6 月 11 日， Capst ...

Our next guest needs no introduction. Tony Robbins. You have to figure it out.Like I always say, if you want to take the island, you burn the boats. I got a chance to work with the president of the United States. Uh Clinton, and he calls me one day, true story, and says, "Tony, they're going to impeach me in the morning." How many of you ever achieved a goal you worked your guts out for and then achieved it and went, "Is this all there is?" Horrific.Horrible. It's great to uh meet you. Thank you.You're bigg ...

Ocugen Inc. (NASDAQ: OCGN ) is a clinical-stage biotechnology company developing an interesting pipeline of modifier gene therapies for rare inherited retinal diseases. In particular, their focus is on those diseases that cause progressive vision lossMy name is Myriam Hernandez Alvarez. I received the Electronics and Telecommunication Engineering degree from the Escuela Politecnica Nacional, Quito, Ecuador, the M.Sc. degree in computer science from Ohio University, Athens, OH, USA, a graduate degree in Busi ...

[Tepuk tangan] Hai everyone. Kalau tadi BDB-nya sudah bicara tentang seni, saya akan melanjutkan juga tentang seni. saya sebagai seniman ee khususnya saya adalah pelukis di mana saya bergerak juga ee di bidang untuk art terapi di mana kalau tadi saya melihat sungguh luar biasa bahwa seni itu menjadi hidup.Seni itu adalah satu cara di mana kita bisa berkomunikasi dengan siapapun. Seni itu seperti satu rangkaian di mana semua bisa melakukannya. Kenapa saya tiba-tiba ada di art terapi.Saya ingin sekali menyamp ...

BioRestorative Therapies (BRTX) Update / Briefing June 18, 2025 10:50 AM ET Speaker0 Thank you so much. Hey, Zakers, and welcome back to All Access. I got that wonderful guest for you today, another one, and that's Lance Allstott, the Chairman and CEO of Bio Restorative Therapies. The NASDAQ ticker is BRTX. He's joining us for another exclusive talk today. All Access starts right now. And it is my pleasure to welcome back in the Chairman and CEO of BioRestorative Therapies, Lance Allstad. It's fantastic to ...

Aptevo Therapeutics Inc APVO stock is surging on Wednesday.As per data from Benzinga Pro, the stock is trading higher with a strong volume of 81.8 million compared to the average volume of 275.3k.What Happened: Aptevo revealed new clinical data from its ongoing Phase 1b/2 RAINIER trial evaluating mipletamig, its first-in-class CD123 x CD3 bispecific antibody, in combination with standard-of-care venetoclax and azacitidine (ven/aza) for newly diagnosed patients with acute myeloid leukemia (AML) who are unfit ...